{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:38:03Z","timestamp":1791261483599,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,12,11]],"date-time":"2012-12-11T00:00:00Z","timestamp":1355184000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1007\/s00280-012-2033-5","type":"journal-article","created":{"date-parts":[[2012,12,10]],"date-time":"2012-12-10T09:01:42Z","timestamp":1355130102000},"page":"581-591","source":"Crossref","is-referenced-by-count":52,"title":["Acadesine for patients with relapsed\/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I\/II study"],"prefix":"10.1007","volume":"71","author":[{"given":"Eric","family":"Van Den Neste","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Cazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Janssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Gonz\u00e1lez-Barca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Terol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"P\u00e9rez de Oteyza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Zachee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"de Frias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Camp\u00e0s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,11]]},"reference":[{"key":"2033_CR1","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0140-6736(08)60456-0","volume":"371","author":"G Dighiero","year":"2008","unstructured":"Dighiero G, Hamblin TJ (2008) Chronic lymphocytic leukaemia. Lancet 371:1017\u20131029","journal-title":"Lancet"},{"key":"2033_CR2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nrclinonc.2009.72","volume":"6","author":"L Pleyer","year":"2009","unstructured":"Pleyer L, Egle A, Hartmann TN, Greil R (2009) Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol 6:405\u2013418","journal-title":"Nat Rev Clin Oncol"},{"key":"2033_CR3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.blre.2010.03.004","volume":"24","author":"T Butler","year":"2010","unstructured":"Butler T, Gribben JG (2010) Biologic and clinical significance of molecular profiling in chronic lymphocytic leukemia. Blood Rev 24:135\u2013141","journal-title":"Blood Rev"},{"key":"2033_CR4","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grunhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jager U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Buhler A, Winkler D, Zenz T, Bottcher S, Ritgen M, Mendila M, Kneba M, Dohner H, Stilgenbauer S, International Group of Investigators, German Chronic Lymphocytic Leukaemia Study Group (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376:1164\u20131174","journal-title":"Lancet"},{"key":"2033_CR5","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2010-08-304683","volume":"117","author":"XC Badoux","year":"2011","unstructured":"Badoux XC, Keating MJ, Wang X, O\u2019Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG (2011) Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 117:3016\u20133024","journal-title":"Blood"},{"key":"2033_CR6","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","volume":"28","author":"T Robak","year":"2010","unstructured":"Robak T, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Geisler CH, Montillo M, Zyuzgin I, Ganly PS, Dartigeas C, Rosta A, Maurer J, Mendila M, Saville MW, Valente N, Wenger MK, Moiseev SI (2010) Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 28:1756\u20131765","journal-title":"J Clin Oncol"},{"key":"2033_CR7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/bmb\/ldn034","volume":"87","author":"AD Hamblin","year":"2008","unstructured":"Hamblin AD, Hamblin TJ (2008) The immunodeficiency of chronic lymphocytic leukaemia. Br Med Bull 87:49\u201362","journal-title":"Br Med Bull"},{"key":"2033_CR8","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1586\/era.10.127","volume":"10","author":"JG Gribben","year":"2010","unstructured":"Gribben JG (2010) Chronic lymphocytic leukemia: planning for an aging population. Expert Rev Anticancer Ther 10:1389\u20131394","journal-title":"Expert Rev Anticancer Ther"},{"key":"2033_CR9","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","volume":"28","author":"T Zenz","year":"2010","unstructured":"Zenz T, Eichhorst B, Busch R, Denzel T, Habe S, Winkler D, Buhler A, Edelmann J, Bergmann M, Hopfinger G, Hensel M, Hallek M, Dohner H, Stilgenbauer S (2010) TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 28:4473\u20134479","journal-title":"J Clin Oncol"},{"key":"2033_CR10","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"H Dohner","year":"2000","unstructured":"Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M, Lichter P (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910\u20131916","journal-title":"N Engl J Med"},{"key":"2033_CR11","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1517\/13543781003703694","volume":"19","author":"E Neste Van Den","year":"2010","unstructured":"Van Den Neste E, Van den Berghe G, Bontemps F (2010) AICA-riboside (acadesine), an activator of AMP-activated protein kinase with potential for application in hematologic malignancies. Expert Opin Investig Drugs 19:571\u2013578","journal-title":"Expert Opin Investig Drugs"},{"key":"2033_CR12","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/j.1552-4604.1993.tb01929.x","volume":"33","author":"R Dixon","year":"1993","unstructured":"Dixon R, Fujitaki J, Sandoval T, Kisicki J (1993) Acadesine (AICA-riboside): disposition and metabolism of an adenosine-regulating agent. J Clin Pharmacol 33:955\u2013958","journal-title":"J Clin Pharmacol"},{"key":"2033_CR13","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1517\/14656566.9.12.2137","volume":"9","author":"BG Drew","year":"2008","unstructured":"Drew BG, Kingwell BA (2008) Acadesine, an adenosine-regulating agent with the potential for widespread indications. Expert Opin Pharmacother 9:2137\u20132144","journal-title":"Expert Opin Pharmacother"},{"key":"2033_CR14","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/blood-2002-07-2339","volume":"101","author":"C Campas","year":"2003","unstructured":"Campas C, Lopez JM, Santidrian AF, Barragan M, Bellosillo B, Colomer D, Gil J (2003) Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes. Blood 101:3674\u20133680","journal-title":"Blood"},{"key":"2033_CR15","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1182\/blood-2010-05-283960","volume":"116","author":"AF Santidrian","year":"2010","unstructured":"Santidrian AF, Gonzalez-Girones DM, Iglesias-Serret D, Coll-Mulet L, Cosialls AM, de Frias M, Campas C, Gonzalez-Barca E, Alonso E, Labi V, Viollet B, Benito A, Pons G, Villunger A, Gil J (2010) AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells. Blood 116:3023\u20133032","journal-title":"Blood"},{"key":"2033_CR16","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/sj.cdd.4401194","volume":"10","author":"I Sturm","year":"2003","unstructured":"Sturm I, Bosanquet AG, Hermann S, Guner D, Dorken B, Daniel PT (2003) Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 10:477\u2013484","journal-title":"Cell Death Differ"},{"key":"2033_CR17","unstructured":"Pairet S, Ferrer A, Abella E, Vela M, Longar\u00f3n R, Camp\u00e0s C, de Frias M, Espinet B, Besses C, Serrano S, Bellosillo B (EHA meeting abstracts) (2010) Acadesine-induced citotoxicity in chronic lymphocytic leukemia is independent of immunoglobulin mutational status and Zap70 expression. Haematologica 95(suppl 2):313, abstract no. 0753"},{"key":"2033_CR18","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ, International Workshop on Chronic Lymphocytic Leukemia (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446\u20135456","journal-title":"Blood"},{"key":"2033_CR19","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0022-5223(05)80179-5","volume":"110","author":"P Menasche","year":"1995","unstructured":"Menasche P, Jamieson WR, Flameng W, Davies MK (1995) Acadesine: a new drug that may improve myocardial protection in coronary artery bypass grafting. Results of the first international multicenter study. Multinational Acadesine Study Group. J Thorac Cardiovasc Surg 110:1096\u20131106","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2033_CR20","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jacc.2006.04.044","volume":"48","author":"DT Mangano","year":"2006","unstructured":"Mangano DT, Miao Y, Tudor IC, Dietzel C, Investigators of the Multicenter Study of Perioperative Ischemia (McSPI) Research Group, Ischemia Research and Education Foundation (IREF) (2006) Post-reperfusion myocardial infarction: long-term survival improvement using adenosine regulation with acadesine. J Am Coll Cardiol 48:206\u2013214","journal-title":"J Am Coll Cardiol"},{"key":"2033_CR21","doi-asserted-by":"crossref","unstructured":"Montraveta A, de Frias M, Camp\u00e0s C, Campo E, Roue G, Colomer D (ASH Annual Meeting Abstracts), (2010) The Nucleoside Analogue Acadesine Exerts Antitumoral Activity and Cooperates with Conventional Agents In In Vitro and In Vivo Models of Mantle Cell Lymphoma Blood 116:3918-Abstract 3918","DOI":"10.1158\/1535-7163.TARG-11-A209"},{"key":"2033_CR22","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1016\/j.yexcr.2007.06.020","volume":"313","author":"P Baumann","year":"2007","unstructured":"Baumann P, Mandl-Weber S, Emmerich B, Straka C, Schmidmaier R (2007) Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells. Exp Cell Res 313:3592\u20133603","journal-title":"Exp Cell Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-012-2033-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-2033-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-2033-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T17:59:34Z","timestamp":1562435974000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-012-2033-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,11]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["2033"],"URL":"https:\/\/doi.org\/10.1007\/s00280-012-2033-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,11]]}}}